Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Subclinical Hypothyroidism After 131I-Treatment of Graves’ Disease: A Risk Factor for Depression?
source: PloS One
year: 2016
authors: Yu J, Tian AJ, Yuan X, Cheng XX
summary/abstract:Objectives:
Although it is well accepted that there is a close relationship between hypothyroidism and depression, previous studies provided inconsistent or even opposite results in whether subclinical hypothyroidism (SCH) increased the risk of depression. One possible reason is that the etiology of SCH in these studies was not clearly distinguished. We therefore investigated the relationship between SCH resulting from 131I treatment of Graves’ disease and depression.
Design and Methods:
The incidence of depression among 95 patients with SCH and 121 euthyroid patients following 131I treatment of Graves’ disease was studied. The risk factors of depression were determined with multivariate logistic regression analysis. Thyroid hormone replacement therapy was performed in patients with thyroid-stimulating hormone (TSH) levels exceeding 10 mIU/L.
Results:
Patients with SCH had significantly higher Hamilton Depression Scale scores, serum TSH and thyroid peroxidase antibody (TPOAb) levels compared with euthyroid patients. Multivariate logistic regression analysis revealed SCH, Graves’ eye syndrome and high serum TPO antibody level as risk factors for depression. L-thyroxine treatment is beneficial for SCH patients with serum TSH levels exceeding 10 mIU/L.
Conclusions:
The results of the present study demonstrated that SCH is prevalent among 131I treated Graves’ patients. SCH might increase the risk of developing depression. L-thyroxine replacement therapy helps to resolve depressive disorders in SCH patients with TSH > 10mIU/L. These data provide insight into the relationship between SCH and depression.
DOI: 10.1371/journal.pone.0154846
read more full text
myBinderRelated Content
-
Thyroid StormThyroid storm is a very rare, but life-t...
-
New Therapeutic Horizons for Graves’ HyperthyroidismGraves’ hyperthyroidism is characteriz...
-
Cancer Mortality Following Treatment for Adult HyperthyroidismContext: High-dose iodine 131 is the tr...
-
2018 European Thyroid Association Guideline for the Management of Graves’ HyperthyroidismGraves' disease (GD) is a systemic autoi...
-
Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves HyperthyroidismContext: Supplemental selenium (Se) may...
-
Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves’ Disease By Early Initiatio...Background: Radioactive iodine (RAI) th...
-
Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317)131I radioiodine therapy (RIT) has been ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google